Data	O
collection	O
and	O
management	O

Baseline	O
data	O
,	O
which	O
included	O
demographics	O
,	O
anthropometrics	O
,	O
comorbid	O
conditions	O
,	O
vital	O
signs	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
scores	O
,	O
and	O
Glasgow	O
coma	O
scale	O
(	O
GCS	O
)	O
scores	O
,	O
were	O
obtained	O
on	O
the	O
day	O
of	O
randomization	O
.	O

Laboratory	O
data	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
scores	O
,	O
PaO2	O
/	O
FiO2	O
,	O
and	O
other	O
treatments	O
used	O
were	O
monitored	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
7	O
(	O
day	O
1	O
was	O
defined	O
as	O
the	O
day	O
of	O
the	O
first	O
administration	O
of	O
vitamin	O
C	O
)	O
.	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
was	O
IMV	B-PrimaryOutcome
-	I-PrimaryOutcome
free	I-PrimaryOutcome
days	I-PrimaryOutcome
in	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
(	O
IMVFD28	O
)	O
.	O

Secondary	O
outcomes	O
included	O
28	B-TimeFrame
-	I-TimeFrame
day	I-TimeFrame
mortality	B-SecondaryOutcome
,	O
organ	B-SecondaryOutcome
functions	I-SecondaryOutcome
and	O
inflammatory	B-SecondaryOutcome
parameters	I-SecondaryOutcome
,	I-SecondaryOutcome
including	I-SecondaryOutcome
white	I-SecondaryOutcome
blood	I-SecondaryOutcome
cell	I-SecondaryOutcome
counts	I-SecondaryOutcome
,	I-SecondaryOutcome
neutrophil	I-SecondaryOutcome
counts	I-SecondaryOutcome
,	I-SecondaryOutcome
lymphocyte	I-SecondaryOutcome
counts	I-SecondaryOutcome
,	I-SecondaryOutcome
procalcitonin	I-SecondaryOutcome
,	I-SecondaryOutcome
interleukin	I-SecondaryOutcome
-	I-SecondaryOutcome
6	I-SecondaryOutcome
(	I-SecondaryOutcome
IL	I-SecondaryOutcome
-	I-SecondaryOutcome
6	I-SecondaryOutcome
)	I-SecondaryOutcome
,	I-SecondaryOutcome
and	I-SecondaryOutcome
C	I-SecondaryOutcome
-	I-SecondaryOutcome
reactive	I-SecondaryOutcome
protein	I-SecondaryOutcome
(	I-SecondaryOutcome
CRP	I-SecondaryOutcome
)	I-SecondaryOutcome
.	O

Multi	O
-	O
organ	O
dysfunction	O
was	O
assessed	O
using	O
SOFA	O
scores	O
.	O
Additionally	O
,	O
vasopressor	B-SecondaryOutcome
days	I-SecondaryOutcome
,	O
respiratory	B-SecondaryOutcome
support	I-SecondaryOutcome
days	I-SecondaryOutcome
,	O
invasive	B-SecondaryOutcome
mechanical	I-SecondaryOutcome
ventilation	I-SecondaryOutcome
(	I-SecondaryOutcome
IMV	I-SecondaryOutcome
)	I-SecondaryOutcome
-	I-SecondaryOutcome
free	I-SecondaryOutcome
days	I-SecondaryOutcome
,	O
patient	B-SecondaryOutcome
condition	I-SecondaryOutcome
improvement	I-SecondaryOutcome
rate	I-SecondaryOutcome
,	O
patient	B-SecondaryOutcome
condition	I-SecondaryOutcome
deterioration	I-SecondaryOutcome
rate	I-SecondaryOutcome
,	O
length	B-SecondaryOutcome
of	I-SecondaryOutcome
ICU	I-SecondaryOutcome
and	I-SecondaryOutcome
hospital	I-SecondaryOutcome
stay	I-SecondaryOutcome
,	O
ICU	B-SecondaryOutcome
and	I-SecondaryOutcome
in	I-SecondaryOutcome
-	I-SecondaryOutcome
hospital	I-SecondaryOutcome
mortality	I-SecondaryOutcome
were	O
recorded	O
as	O
additional	O
secondary	O
outcomes	O
of	O
this	O
research	O
.	O

IMV	O
-	O
free	O
days	O
were	O
defined	O
as	O
the	O
number	B-OutcomeDefinition
of	I-OutcomeDefinition
days	I-OutcomeDefinition
a	I-OutcomeDefinition
patient	I-OutcomeDefinition
was	I-OutcomeDefinition
extubated	I-OutcomeDefinition
after	B-TimeFrame
recruitment	I-TimeFrame
to	I-TimeFrame
day	I-TimeFrame
28	I-TimeFrame
.	O

If	O
the	O
patient	O
died	O
with	O
MV	O
,	O
a	O
value	O
of	O
zero	O
was	O
assigned	O
.	O

Deterioration	O
of	O
the	O
patient	O
’	O
s	O
condition	O
was	O
defined	B-OutcomeDefinition
as	I-OutcomeDefinition
the	I-OutcomeDefinition
patient	I-OutcomeDefinition
requiring	I-OutcomeDefinition
HFNC	I-OutcomeDefinition
or	I-OutcomeDefinition
NIV	I-OutcomeDefinition
on	I-OutcomeDefinition
day	I-OutcomeDefinition
1	I-OutcomeDefinition
and	I-OutcomeDefinition
requiring	I-OutcomeDefinition
ECMO	I-OutcomeDefinition
or	I-OutcomeDefinition
IMV	I-OutcomeDefinition
,	I-OutcomeDefinition
or	I-OutcomeDefinition
dying	I-OutcomeDefinition
,	I-OutcomeDefinition
after	I-OutcomeDefinition
7	I-OutcomeDefinition
days	I-OutcomeDefinition
of	I-OutcomeDefinition
treatment	I-OutcomeDefinition
.	O

Improvement	O
of	O
the	O
patient	O
’	O
s	O
condition	O
was	O
defined	B-OutcomeDefinition
as	I-OutcomeDefinition
the	I-OutcomeDefinition
patient	I-OutcomeDefinition
requiring	I-OutcomeDefinition
ECMO	I-OutcomeDefinition
or	I-OutcomeDefinition
IMV	I-OutcomeDefinition
on	I-OutcomeDefinition
day	I-OutcomeDefinition
1	I-OutcomeDefinition
and	I-OutcomeDefinition
switching	I-OutcomeDefinition
to	I-OutcomeDefinition
HFNC	I-OutcomeDefinition
,	I-OutcomeDefinition
NIV	I-OutcomeDefinition
,	I-OutcomeDefinition
or	I-OutcomeDefinition
discharged	I-OutcomeDefinition
from	I-OutcomeDefinition
the	I-OutcomeDefinition
ICU	I-OutcomeDefinition
after	I-OutcomeDefinition
7	I-OutcomeDefinition
days	I-OutcomeDefinition
of	I-OutcomeDefinition
treatment	I-OutcomeDefinition
.	O

The	O
P	O
/	O
F	O
was	O
calculated	O
based	O
on	O
the	O
PaO2	O
/	O
FiO2	O
,	O
and	O
we	O
choose	O
the	O
lowest	O
values	O
recorded	O
on	O
the	O
specific	O
day	O
.	O

All	O
the	O
data	O
were	O
collected	O
from	O
the	O
clinical	O
information	O
system	O
of	O
three	O
ICUs	O
.	O

